drugset / Trial / NCT01011374
Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, single-center, non-randomized clinical study on the impact of intravitreally administered ranibizumab (Lucentis) treatment on vision-related functioning and emotional well-being in subjects with central or branch retinal vein occlusion.
Timeline
- Start
- 2009-11
- Primary completion
- 2012-11
- Completion
- 2013-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |